Quick Answer
Moderna, Inc. reported Total Revenue of $1.94 billion for the year ending 2025.
- Moderna, Inc. showed a decrease of -39.9% in Total Revenue from 2024 to 2025.
- This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2016 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $30.33 million | Q2 2017: $41.12 million | Q3 2017: $42.47 million | Q4 2017: $91.90 million | Q1 2018: $29.04 million | Q2 2018: $28.85 million | Q3 2018: $41.76 million | Q4 2018: $35.42 million | Q1 2019: $16.03 million | Q2 2019: $13.08 million | Q3 2019: $17.05 million | Q4 2019: $14.06 million | Q1 2020: $8.00 million | Q2 2020: $67.00 million | Q3 2020: $157.00 million | Q1 2021: $1.94 billion | Q2 2021: $4.35 billion | Q3 2021: $4.97 billion | Q1 2022: $6.07 billion | Q2 2022: $4.75 billion | Q3 2022: $3.36 billion | Q3 2022: $3.36 billion | Q1 2023: $1.86 billion | Q1 2023: $1.86 billion | Q2 2023: $344.00 million | Q2 2023: $344.00 million | Q3 2023: $1.83 billion | Q1 2024: $167.00 million | Q2 2024: $241.00 million | Q3 2024: $1.86 billion | Q1 2025: $108.00 million | Q2 2025: $142.00 million | Q3 2025: $1.02 billion.
- Over the full 12 years of available data (2016 to 2025), Moderna, Inc.'s Total Revenue has grown by 1,693.4%.
- Historical annual values: Fiscal year 2025: $1.94 billion | Fiscal year 2024: $3.24 billion | Fiscal year 2023: $6.85 billion | Fiscal year 2022: $19.26 billion | Fiscal year 2022: $19.26 billion | Fiscal year 2021: $18.47 billion | Fiscal year 2021: $18.47 billion | Fiscal year 2020: $803.00 million | Fiscal year 2019: $60.00 million | Fiscal year 2018: $135.07 million | Fiscal year 2017: $205.83 million | Fiscal year 2016: $108.40 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: